News
After the GLP-1 shortage era: what compounders and telehealth desks are watching
FDA's post-shortage compounding reminders and "essentially a copy" framing are reshaping playbooks for 503A pharmacies, 503B facilities, and virtual prescribing programs.
When branded GLP-1 injectables moved off FDA's shortage list, the operational question for many telehealth and pharmacy teams became what documentation and volume limits still hold under 503A and 503B. FDA's April 1, 2026 update reminds compounders of "essentially a copy" conditions and 503B bulk-substance limits.